Clinical Trial: Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

Brief Summary: This is a extension study of CSTI571B1201 study

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: To study the antineoplastic effect of the investigational drug.

Original Primary Outcome:

Current Secondary Outcome: To study the safety and pharmacokinetics of the investigational drug.

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: October 9, 2005
Date Started: September 2002
Date Completion:
Last Updated: April 29, 2012
Last Verified: April 2012